CRIS Current Research Information System

STEFONI, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.181
EU - Europa 7.066
NA - Nord America 6.652
AF - Africa 359
SA - Sud America 345
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 3
Totale 21.620
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.548
VN - Vietnam 2.175
NL - Olanda 2.114
SG - Singapore 1.865
CN - Cina 1.686
DE - Germania 984
IT - Italia 948
GB - Regno Unito 880
SE - Svezia 775
HK - Hong Kong 501
FR - Francia 300
IN - India 274
RU - Federazione Russa 264
BR - Brasile 250
UA - Ucraina 197
IE - Irlanda 169
KR - Corea 167
JP - Giappone 117
FI - Finlandia 100
TG - Togo 93
CI - Costa d'Avorio 85
ZA - Sudafrica 78
JO - Giordania 65
CA - Canada 64
EE - Estonia 57
HR - Croazia 49
PL - Polonia 48
AR - Argentina 44
NG - Nigeria 43
PH - Filippine 42
BD - Bangladesh 39
ID - Indonesia 37
BE - Belgio 36
TH - Thailandia 34
CH - Svizzera 32
SC - Seychelles 29
ES - Italia 28
AT - Austria 26
TW - Taiwan 26
MX - Messico 25
IQ - Iraq 24
TR - Turchia 24
IR - Iran 22
BG - Bulgaria 15
UZ - Uzbekistan 13
EC - Ecuador 12
SA - Arabia Saudita 12
MY - Malesia 11
AU - Australia 8
CL - Cile 8
KE - Kenya 8
PY - Paraguay 8
LB - Libano 7
PE - Perù 7
RO - Romania 7
EG - Egitto 6
GR - Grecia 6
LT - Lituania 6
VE - Venezuela 6
BO - Bolivia 5
IL - Israele 5
PK - Pakistan 5
PS - Palestinian Territory 5
RS - Serbia 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
KZ - Kazakistan 4
NZ - Nuova Zelanda 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CO - Colombia 3
CZ - Repubblica Ceca 3
MA - Marocco 3
OM - Oman 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
BW - Botswana 2
DK - Danimarca 2
ET - Etiopia 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
MN - Mongolia 2
NO - Norvegia 2
PA - Panama 2
PT - Portogallo 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
BY - Bielorussia 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
DZ - Algeria 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
GY - Guiana 1
Totale 21.606
Salva come PNG Salva come JPEG
Città #
Singapore 1.305
Eygelshoven 1.286
Southend 744
Ashburn 710
Kerkrade 666
Fairfield 624
Chandler 508
Hong Kong 468
Ho Chi Minh City 455
Frankfurt am Main 390
Hanoi 350
Santa Clara 340
Hefei 338
Houston 324
Woodbridge 314
San Jose 298
Seattle 278
Ann Arbor 269
Wilmington 256
Dong Ket 255
Cambridge 220
Beijing 215
Princeton 206
Dublin 169
Boardman 156
Seoul 150
Bologna 149
Los Angeles 123
Lauterbourg 113
Milan 107
Jacksonville 101
New York 101
Tokyo 96
Lomé 93
Berlin 88
Abidjan 85
Nanjing 81
Helsinki 79
Westminster 78
Padova 68
Amman 65
Da Nang 65
Buffalo 61
Rome 56
Jinan 55
Bremen 53
Turin 53
Haiphong 52
Shenyang 47
Falkenstein 43
Abeokuta 39
São Paulo 38
San Diego 35
Council Bluffs 34
Changsha 33
Guangzhou 32
Kyiv 32
Warsaw 32
Saint Petersburg 31
Chicago 30
Jiaxing 30
Toronto 30
Bengaluru 29
Florence 29
Munich 29
Redwood City 29
Zhengzhou 28
Brussels 27
Nanchang 27
Dallas 26
The Dalles 26
London 25
Dearborn 24
Des Moines 24
Düsseldorf 24
Redondo Beach 24
Hyderabad 23
Nuremberg 23
Hebei 22
Bern 21
Hangzhou 21
Modena 20
Shanghai 20
Tianjin 20
Amsterdam 19
Falls Church 19
Hải Dương 19
Jakarta 19
Phoenix 18
Quận Bình Thạnh 18
Secaucus 18
Orem 16
Redmond 16
Taizhou 16
Yubileyny 16
Brooklyn 15
Can Tho 15
Lappeenranta 15
Mülheim 15
Biên Hòa 14
Totale 14.411
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.841
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 427
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 283
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 251
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 246
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 244
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 241
18 F-FDG PET in malignant lymphoma: significance of positive findings 238
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 237
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 235
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 232
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 232
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 231
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 223
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 222
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 221
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 216
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 214
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 214
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 212
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 210
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 207
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 206
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 205
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 201
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 199
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 199
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 199
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 196
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 194
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 193
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 193
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 190
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 189
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 188
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 185
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 181
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 181
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 179
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 178
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 173
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 173
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 171
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 169
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 169
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 169
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 169
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 169
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 168
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 167
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 165
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 164
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 164
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 163
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 163
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 162
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 162
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. 161
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 161
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. 160
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 160
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 160
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 158
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 157
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 154
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 152
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 152
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. 151
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 150
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 149
Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. 147
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 147
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 147
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 146
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 145
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 144
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine 143
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 142
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 139
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 139
Rituximab in primary conjunctiva lymphoma. 138
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 137
Corrigendum: Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient (Frontiers in Pediatrics, (2021), 9, (702546), 10.3389/fped.2021.702546) 133
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 131
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 130
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 129
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 129
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. 127
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 127
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. 125
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 123
Clinical significance of axillary findings in patients with lymphoma during follow up. C 122
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 122
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 121
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. 120
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 120
Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient 116
Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas 115
Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis 115
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy 110
Totale 20.127
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.307
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.307
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021749 0 0 0 0 0 0 0 0 0 61 92 596
2021/20222.113 310 54 132 258 149 98 37 133 61 145 425 311
2022/20232.366 246 346 159 300 177 185 52 140 413 68 159 121
2023/2024744 62 112 57 93 59 106 48 44 26 53 33 51
2024/20253.348 136 417 259 205 502 185 309 90 62 300 164 719
2025/20268.642 584 828 565 454 748 1.690 1.655 194 1.461 463 0 0
Totale 21.977